IBIO iBio Inc

Price (delayed)

$2.44

Market cap

$21.04M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$4.87

Enterprise value

$32.57M

iBio is a global leader in plant-based biologics manufacturing. Its FastPharmingĀ® System combines vertical farming, automated hydroponics, and novel glycosylation technologies to rapidly deliver high-quality monoclonal antibodies, vaccines, bioinks and ...

Highlights
The company's equity has surged by 170% QoQ and by 43% YoY
The EPS has soared by 97% YoY and by 68% from the previous quarter
IBIO's quick ratio has soared by 58% from the previous quarter but it is down by 38% YoY
IBIO's debt is up by 4% from the previous quarter but it is down by 2.6% YoY

Key stats

What are the main financial stats of IBIO
Market
Shares outstanding
8.62M
Market cap
$21.04M
Enterprise value
$32.57M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.34
Price to sales (P/S)
181.19
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
651.36
Earnings
Revenue
$50,000
EBIT
-$23.03M
EBITDA
-$21.76M
Free cash flow
-$17.63M
Per share
EPS
-$4.87
Free cash flow per share
-$4.75
Book value per share
$7.14
Revenue per share
$0.01
TBVPS
$12.06
Balance sheet
Total assets
$50.15M
Total liabilities
$25.29M
Debt
$17.96M
Equity
$24.86M
Working capital
$14.71M
Liquidity
Debt to equity
0.72
Current ratio
1.69
Quick ratio
0.3
Net debt/EBITDA
-0.53
Margins
EBITDA margin
-43,518%
Gross margin
100%
Net margin
-46,324%
Operating margin
-36,380%
Efficiency
Return on assets
-56.8%
Return on equity
-147.9%
Return on invested capital
-89.4%
Return on capital employed
-80.2%
Return on sales
-46,066%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

IBIO stock price

How has the iBio stock price performed over time
Intraday
12.96%
1 week
27.08%
1 month
-4.31%
1 year
-79.44%
YTD
78.1%
QTD
15.64%

Financial performance

How have iBio's revenue and profit performed over time
Revenue
$50,000
Gross profit
$50,000
Operating income
-$18.19M
Net income
-$23.16M
Gross margin
100%
Net margin
-46,324%
The company's net income has surged by 70% YoY and by 15% QoQ
The operating income has increased by 48% year-on-year and by 12% since the previous quarter
IBIO's net margin is up by 15% from the previous quarter
The company's operating margin rose by 12% QoQ

Growth

What is iBio's growth rate over time

Valuation

What is iBio stock price valuation
P/E
N/A
P/B
0.34
P/S
181.19
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
651.36
The EPS has soared by 97% YoY and by 68% from the previous quarter
The company's equity has surged by 170% QoQ and by 43% YoY
IBIO's price to book (P/B) is 87% lower than its 5-year quarterly average of 2.7 and 32% lower than its last 4 quarters average of 0.5
IBIO's price to sales (P/S) is 113% more than its 5-year quarterly average of 84.9

Efficiency

How efficient is iBio business performance
iBio's return on assets has increased by 48% YoY and by 18% QoQ
The ROIC has grown by 47% YoY and by 23% from the previous quarter
iBio's return on equity has increased by 28% YoY and by 25% QoQ
The ROS has grown by 15% from the previous quarter

Dividends

What is IBIO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for IBIO.

Financial health

How did iBio financials performed over time
iBio's total assets is 98% more than its total liabilities
IBIO's current ratio has surged by 86% since the previous quarter and by 39% year-on-year
IBIO's quick ratio has soared by 58% from the previous quarter but it is down by 38% YoY
IBIO's debt is 28% less than its equity
The company's equity has surged by 170% QoQ and by 43% YoY
The company's debt to equity has shrunk by 62% QoQ and by 32% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.